The global burden of disease attributable to contaminated injections given in health care settings

International Journal of STD and AIDS

Volumn 15, Issue 1, 2004, Pages 7-16

  Hauri, Anja M ^a   Armstrong, Gregory L ^b   Hutin, Yvan J F ^a  

^a WORLD HEALTH ORGANIZATION   (Switzerland)

^b NATL CENTER FOR INFECTIOUS DISEASES   (United States)

Author keywords

Cross infection; Hepatitis B virus; Hepatitis C virus; HIV; Injections; Mathematical models; Needlestick injuries

Indexed keywords

ARTICLE; CONTROLLED STUDY; CROSS INFECTION; DEVICE INFECTION; HEALTH CARE; HEPATITIS B; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; INFECTION CONTROL; INFECTION PREVENTION; INJECTION; INSTRUMENT STERILIZATION; PRIORITY JOURNAL; SAFETY; VIRUS TRANSMISSION;

CROSS INFECTION; EQUIPMENT CONTAMINATION; HEPATITIS B; HEPATITIS C; HIV INFECTIONS; HUMANS; INCIDENCE; INFECTION CONTROL; INJECTIONS; PREVALENCE; QUALITY-ADJUSTED LIFE YEARS; WORLD HEALTH;

EID: 0347302936     PISSN: 09564624     EISSN: None     Source Type: Journal    
DOI: 10.1258/095646204322637182     Document Type: Article

References (80)

1. Simonsen L, Kane A, Lloyd J, Zaffran M, Kane M. Unsafe injections in the developing world and transmission of blood-borne pathogens. Bull WHO 1999;77:789-800
2. Drucker E, Alcabes PG, Marx PA. The injection century: massive unsterile injections and the emergence of human pathogens. Lancet 2001;358:1989-92
3. Reeler AV. Injections: a fatal attraction? Soc Sci Med 1990;31:1129-35
4. Frank C, Mohamed MK, Strickland GT, et al. The role of parenteral antischistosomal therapy in the spread of hepatitis C virus in Egypt. Lancet 2000;355:887-91
5. Hutin YJF, Hauri AM, Armstrong GL. Overuse and Unsafe Use of Injections in Health Care Setting Worldwide, 2000. BMJ 2003; in press
6. Shikata T, Karasaw T, Abe K, et al. Hepatitis B e antigens and infectivity of hepatitis B virus. J Infect Dis 1977;136:571
7. Choo QL, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 1989;244:359-62
8. Molina JM, Ferchal F, Chevret S, et al. Quantification of HIV-1 virus load under zidovudine therapy in patients with symptomatic HIV infection: relation to disease progression. AIDS 1994;8:27-33
9. Senior JR, Sutnick AI, Goeser E, London WT, Dahlke MB, Blumberg BS. Reduction of post-transfusion hepatitis by exclusion of Australia antigen from donor blood in an urban public hospital. Am J Med Sci 1974;267:171-7
10. Aach RD, Stevens CE, Hollinger FB, et al. Hepatitis C virus infection in post-transfusion hepatitis. N Engl J Med 1991;325:1325-9
11. Busch MP, Operskalski EA, Mosley JW, et al. Factors influencing human immunodeficiency virus type 1 transmission by blood transfusion. J Infect Dis 1996;174:26-33
12. Seeff LB, Wright EC, Zimmerman HJ, Alter HJ, Dietz AA, Felsher BF. Type B hepatitis after needle-stick exposure: prevention with hepatitis B immune globulin. Final report of the Veterans Administration Cooperative Study. Ann Intern Med 1978;88:285-93
13. Centers for Disease Control and Prevention. Recommendations for follow-up of health care workers after occupational exposure to hepatitis C virus. MMWR 1997;46:603-6
14. Cardo DM, Culver DH, Ciesielski CA, et al. A case-control study of HIV seroconversion in health care workers after percutaneous exposure. Centers for Disease Control and Prevention Needlestick Surveillance Group. N Engl J Med 1997;337:1542-3
15. Narendranathan M, Philip M. Reusable needles - a major risk factor for acute virus B hepatitis. Trop Doc 1993;23:64-6
16. Luby SP, Qamruddin K, Shah AA, et al. The relationship between therapeutic injections and high prevalence of hepatitis C infection in Hafizabad, Pakistan. Epidemiol Infect 1997;119:349-56
17. Quigley MA, Morgan D, Malamba SS, et al. Case-control study of risk factors for incident HIV infections in rural Uganda. J Acquir Immune Defic Syndr 2000;23:418-25
18. Ko YV, Li SC, Yen YY, Yeh SM, Hsieh CC. Horizontal transmission of hepatitis B virus from siblings and intramuscular injection among preschool children in a familial cohort. Am J Epidemiol 1991;133:1015-23
19. Khan AJ, Luby SP, Fikree FF, et al. Unsafe injections and the transmission of hepatitis B and C in a periurban community in Pakistan. Bull WHO 2000;78:956-63
20. Hutin YJF, Harpaz R, Drobeniuc J, et al. Injections given in healthcare settings as a major source of acute hepatitis B in Moldova. Int J Epidemiol 1999;28:782-6
21. El-Sakka H. Risk Factors for HCV infection. Gharbia Governorate, Egypt, 1996-7. Presentation given at the EIS conference, Atlanta, GA, USA, April 1997
22. Val Mayans M, Hall AJ, Inskip HM, et al. Risk factors for transmission of hepatitis B virus to Gambian children. Lancet 1990;336:1107-9
23. Ko YC, Chung DC. Transmission of hepatitis B virus infection by iatrogenic intramuscular injections in an endemic area. Kaohsiung J Med Sci 1991;7:313-17
24. Hsu SC, Chang MH, Ni YH, Hsu HY, Lee CY. Horizontal transmission of hepatitis B virus in children. J Ped Gastroenterol Nut 1993;16:66-9
25. Thuring EG, Joller-Jemelka HI, Sareth H, Sokhan U, Reth C, Grob P. Prevalence of markers of hepatitis viruses A, B, C and of HIV in healthy individuals and patients of a Cambodian province. Southeast Asian J Trop Med Pub Health 1993;24:239-49
26. Anonymous. Possible risk factor for acute hepatitis B infection, case control study, Qena and Luxor city fever hospitals, 1994. Epidemiol Bull - Egypt 1998;1:6-8
27. Simard E, Wasley A, Pistol A, Popa M, Hutin Y, Mast E. Surveillance for acute hepatitis B among children, Romania, 1997-9. Presentation given at the American Public Health Association meeting, Boston, MA, USA, December 2000
28. Singh J, Bhatia R, Patnaik SK, et al. Community studies on hepatitis B in Rajahmundry town of Andhra Pradesh, India, 1997-8: Unnecessary therapeutic injections are a major risk factor. Epidemiol Infect 2000;125:367-75
29. Hussain R. A case-control study of risk factors for acute hepatitis B virus infection in Karachi, Pakistan. MSc Thesis, Aga Khan University, Karachi, Pakistan, September 2001
30. Chen TZ, Wu JC, Yen FS, et al. Injection with nondisposable needles as an important route for transmission of acute community-acquired hepatitis C virus infection in Taiwan. J Med Virol 1995;46:247-51
31. Chang SJ, Chen HC, Ying J, Lu CF, Ko YC. Risk factors of hepatitis C virus infection in a Taiwanese aboriginal community. Kao Hsiung I Hsueh Ko Hsueh Tsa Chih 1996;12:241-7
32. Mohamed MK, Hussein MH, Massoud AA, et al. Study of the risk factors for viral hepatitis C infection among Egyptians applying for work abroad. J Egypt Pub Health Assoc 1996;71:113-42
33. Ho M-S, Hsu C-P, Yuh Y, et al. High rate of hepatitis C virus infection in an isolated community: persistent hyperendemicity or period-related phenomena? J Med Virol 1997;52:370-6
34. Sun CA, Chen HC, Lu CF, et al. Transmission of hepatitis C virus in Taiwan: prevalence and risk factors based on a nationwide survey. J Med Virol 1999;59:2906
35. Sun CA, Chen HC, Lu SN, et al. Persistent hyperendemicity of hepatitis C virus infection in Taiwan: The important role of iatrogenic risk factors. J Med Virol 2001;65:30-4
36. N'Galy B, Ryder RW, Bila K, et al. Human immunodeficiency virus infection among employees in an African hospital. N Engl J Med 1988;319:1123-7
37. Wawer MJ, Sewankambo NK, Berkley S, et al. Incidence of HIV-1 infection in a rural region of Uganda. BMJ 1994;308:171-3
38. Bulterys M, Chao A, Habimana P, et al. Incident HIV-1 infection in a cohort of young women in Butare, Rwanda. AIDS 1994;8:1585-91
39. Murray CL, Lopez AD. On the comparable quantification of health risks: Lessons from the Global Burden of Disease study. Epidemiology 1999;10:594-605
40. Murray CJL, Lopez AD. The global burden of disease: a comprehensive assessment of mortality and disability from diseases, injury and risk factors in 1990 and projected to 2020. Geneva: World Health Organization, 1996
41. Aylward B, Kane M, McNair-Scott R, Hu DJ. Model-based estimates of the risk of human immunodeficiency virus and hepatitis B virus transmission through unsafe injections. Int J Epidemiol 1995;24:446-52
42. Kane A, Lloyd J, Zaffran M, Simonsen L, Kane M. Transmission of hepatitis B, hepatitis C and human immunodeficiency viruses through unsafe injections in the developing world. Model-based regional estimates. Bull WHO 1999;77:801-7
43. Soeters R, Aus C. Hazards of injectable therapy. Trop Doc 1989;19:124-6
44. Fontaine O, Diop B, Beau JP, et al. La diarrhée infantile au Sénégal. Med Trop 1984;44:27-31
45. Archibald LK, Ramos M, Arduino MJ, et al. Enterobacter cloacae and Pseudomonas aeruginosa polymicrobial bloodstream infections traced to extrinsic contamination of a dextrose multidose vial. J Pediatr 1998;133:640-4
46. Abulrahi HA, Bohlega EA, Fontaine RE, Al-Seghayer SM, Al-Ruweis AA. Plasmodium falciparum malaria transmitted in hospital through heparin locks. Lancet 1997;349:23-5
47. World Health Organization. Ebola haemorrhagic fever in Zaire, 1976. Bull WHO 1978;56:271-93
48. Fisher-Hoch SP, Tomori O, Nasidi A, et al. Review of cases of nosocomial Lassa fever in Nigeria: the high price of poor medical practice. BMJ 1995;311:857-9
49. Ezzati M, Lopez AD, Rodgers A, Vander Hoorn S, Murray CJL, and the Comparative Risk Assessment Collaborating Group. Selected major risk factors and global and regional burden of disease. Lancet 2002;360:1347-60
50. Gisselquist DP. Estimataing HIV-1 transmission efficiency through unsafe medical injections. Int J STD AIDS 2002;13:152-9
51. Rothenberg RB, Hahn, RA. Measures of attribution. In: C. Haddix, SM, Teusch, PA, Shaffer, DO, Dunet, eds. Prevention effectiveness; a guide to decision analysis and economic evaluation. Oxford: Oxford University Press, 1996
52. Centers for Disease Control and Prevention. Frequency of vaccine-related and therapeutic injection - Romania 1998. MMWR 1999;48:271-4
53. World Health Organization. High frequency of therapeutic injections, Republic of Moldova. Wkly Epidemiol Rec 1999;11:84-6
54. WHO. Hepatitis C: Global prevalence (Update). Wkly Epidemiol Rec 2000;75:18-19
55. UNAIDS: Global HIV Epidemic Update: December 2000. UNAIDS Document, Geneva, Switzerland
56. Murray CJL, Lopez AD, eds. The Global Burden of Disease. A comprehensive assessment of mortality and disability from diseases, injuries and risk factors in 1990 and projected to 2010. Published by the Harvard School of Public Health on behalf of the World Health Organization and the World Bank, 1996
57. McMahon BJ, Alward WL, Hall DB, Heyward WL, Bender TR, Francis DP. Acute hepatitis B virus infection: relation of age to the clinical expression of disease and subsequent development of the carrier stage. J Infect Dis 1985;151: 599-603
58. Alter HJ, Seeff LB. Recovery, persistence and sequelae in hepatitis C virus infection: a perspective on long-term outcome. Semin Liver Dis 2000;20:17-35
59. Alward WL, McMahon BJ, Hall DB, et al. The long-term serological course of asymptomatic hepatitis B virus carriers and the development of primary hepatocellular carcinoma. J Infect Dis 1985;151:604-9
60. Gay NJ, Edmunds WJ, Bah E. Estimating the global burden of hepatitis B. Unpublished manuscript prepared for the Global Burden of Disease study, April 2001
61. Freeman AJ, Dore GJ, Law MG, et al. Estimating progression to cirrhosis in chronic hepatitis C virus infection. Hepatology 2001;34:809-16
62. Karvountziz GG, Redeker AG, Peter RL. Long term follow-up studies of patients surviving fulminant viral hepatitis. Gastroenterology 1974;67:870-7
63. Hoofnagle JH, Shafritz DA, Popper H. Chronic type B hepatitis and the "healthy" HBsAg carrier state. Hepatology 1987;7:758-63
64. Centers for Disease Control. Hepatitis surveillance report. No 52. Atlanta, GA: CDC, 1990
65. National Burden of Disease Studies: A Practical Guide, Edition 2.0. World Health Organization, Global Program on Evidence for Health Policy. WHO, Geneva, October 2001
66. Maynard JE, Kane MA, Hadler SC. Global control of hepatitis B through vaccination role of hepatitis B vaccine in the Expanded Programme on Immunization. Rev Infect Dis 1989;11(Suppl 3):S574-8
67. Alter MJ. Epidemiology of hepatitis C in the West. Semin Liver Dis 1995;15:5-14
68. Williams CL, Mast EE, Coleman PJ, et al. Sexual practices associated with hepatitis C virus infection among non injecting-drug-using female prostitutes in the United States. [Abstract.] Program and Abstracts of the 6th International Symposium on Hepatitis C & Related Viruses: Molecular Virology and Pathogenesis. 6-9 June, 1999, National Institutes of Health, Bethesda, Maryland, 1999
69. Alter MJ, Kruszon-Moran D, Nainan OV, et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med 1999;341:556-62
70. Wasley A, Alter MJ. Epidemiology of hepatitis C: geographic differences and temporal trends. Semin Liver Dis 2000;20:1-16
71. World Bank. HIV transmission through medical injections. Box 2.2. In Confronting AIDS. Public priorities in a global epidemic. Revised edition. Oxford University Press, 1999
72. Gisselquist D, Rothenberg R, Potterat JBA, Drucker E. HIV infections in sub-Saharan Africa not explained by sexual or vertical transmission. Int J STD AIDS 2002;13:657-66
73. Shaldon S. Transmission of HIV in dialysis centres. Lancet 1995;346:451
74. Hersh BS, Popovici F, Jezek Z, et al. Risk factors for HIV infection among abandoned Romanian children. AIDS 1993;7:1617-24
75. Yerly S, Quadri R, Negro F, et al. Nosocomial outbreak of multiple bloodborne viral infections. J Infect Dis 2001;184:369-72
76. Rothenberg RB, Sterk C, Toomey KE, et al. Using social network and ethnographic tools to evaluate syphilis transmission. Sex Transm Dis 1998;25:154-60
77. Potterat JJ, Rothenberg RB, Muth SQ. Network structural dynamics and infectious disease propagation. Int J STD AIDS 1999;10:182-5
78. Katzenstein TL, Jorgensen LB, Permin H, et al. Nosocomial HIV-transmission in an outpatient clinic detected by epidemiological and phylogenetic analyses. AIDS 1999;13:1737-44
79. Centers for Disease Control. Injection practices among nurses - Valcea, Romania, 1998. MMWR 2001;50:59-61
80. World Health Organization: "Aide Mémoire" for a national strategy for the safe and appropriate use of injections. Department of blood safety and clinical technology, 2000